News

The new solution is aimed at helping providers and communities reduce hospital readmissions and re-incarcerations as well as help create more comprehensive patient health records. As of now,

NeoStem Grants and Academic Liaison director Dr Denis O. Rodgerson and Dr Vincent Falanga, The Barbara A. Gilchrest Professor of Dermatology and Professor of Biochemistry at the Boston

Proceeds from the financing will be used to further develop its first two pharmaceutical products and its associated drug delivery technology. The first product is a novel drug-device

Recruitment was temporarily paused due to a drug storage issue which has now been resolved to the satisfaction of the UK Regulatory Body, allowing the trial to continue

Access recently submitted an additional patent application to protect improvements in the technology and expand applications, and is actively seeking development partners globally. Access compared single doses of

These shares became available for purchase by Genzyme as a result of Alnylam’s issuance of shares of common stock to Merck in connection with Alnylam’s acquisition of Sirna

Currently, Precision is advancing its clinical trials with NEO-102, which is being developed as a therapeutic drug candidate for pancreatic and colorectal cancers. As part of the deal,

These new offerings will serve to further the company’s mission of providing innovative service solutions to a variety of businesses throughout the biotech, pharmaceutical, and medical device industries.

Collectively these engagements encompass cloud-based technologies and professional services and training across BioClinica’s full eClinical product suite: OnPoint CTMS, Express EDC, Trident IRT, and clinical supplies Optimizer. Under